Top

Annals of Surgical Oncology

Published in:

01-03-2011 | Translational Research and Biomarkers

Role of Survivin Gene Promoter Polymorphism (−31G>C) in Susceptibility and Survival of Esophageal Cancer in Northern India

Authors: Rohit Upadhyay, MSc, Rohini Khurana, MD, Shaleen Kumar, MD, Uday Chand Ghoshal, DM, Balraj Mittal, PhD

Published in: Annals of Surgical Oncology | Issue 3/2011

Abstract

Background and Aim

Survivin is an upregulated inhibitor of apoptosis protein in esophageal cancer (EC), and a promoter region polymorphism (−31G>C) in the survivin gene has been reported as a modulator of gene expression. We aim to explore the role of survivin −31G>C polymorphism in susceptibility and survival of EC patients in northern Indian population.

Materials and Methods

A case–control study was performed in 500 subjects (250 EC patients and 250 controls), and genotyping was done by polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) method.

Results

Survivin CC genotype was found to be significantly associated with EC susceptibility [odds ratio (OR) = 2.29; 95% confidence interval (CI) = 1.27–4.14; P = 0.006], particularly in males (OR = 4.91; 95% CI = 2.19–11.02; P = 0.0001) having squamous cell carcinoma (SCC) histopathology (OR = 2.4; 95% CI = 1.36–4.21; P = 0.002) at middle third esophagus location (OR = 2.60; 95% CI = 1.40–4.82; P = 0.002). Patients carrying CC genotype were found to have higher susceptibility to lymph node metastasis (OR = 2.82; 95% CI = 1.46–5.48; P = 0.002). However, on survival analysis, no prognostic role of survivin −31G>C polymorphism was detected. In case-only analysis, no gene–environment interaction was observed.

Conclusion

Survivin promoter region polymorphism (−31G>C) is associated with susceptibility and clinical characteristics but not prognosis of esophageal cancer in northern Indian population.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef

Umar SB, Fleischer DE. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol. 2008;5:517–26.CrossRef

Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus. 2006;19:425–32.PubMedCrossRef

Knauer SK, Mann W, Stauber RH. Survivin’s dual role: an export’s view. Cell Cycle. 2007;6:518–21.PubMedCrossRef

Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–82.PubMedCrossRef

Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–89.PubMedCrossRef

O’Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 2000;156:393–8.PubMedCrossRef

Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol. 2004;41:599–607.PubMedCrossRef

Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076–81.PubMedCrossRef

10.

Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999;23:387–8.PubMedCrossRef

11.

Nemoto T, Kitagawa M, Hasegawa M, et al. Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol. 2004;76:253–9.PubMedCrossRef

12.

Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–5.PubMedCrossRef

13.

Zhu HX, Wang YH, Zhou CQ, et al. [Expression of survivin and its significance in esophageal cancer]. Zhonghua Zhong Liu Za Zhi. 2005;27:22–4.PubMed

14.

Sato F, Abraham JM, Yin J, et al. Polo-like kinase and survivin are esophageal tumor-specific promoters. Biochem Biophys Res Commun. 2006;342:465–71.PubMedCrossRef

15.

Martinez A, Bellosillo B, Bosch F, et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol. 2004;164:501–10.PubMedCrossRef

16.

Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett. 2002;184:105–16.PubMedCrossRef

17.

Wurl P, Kappler M, Meye A, et al. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet. 2002;359:943–5.PubMedCrossRef

18.

Cao M, Yie SM, Wu SM, et al. Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis. 2009;26:751–8.PubMedCrossRef

19.

Rosato A, Pivetta M, Parenti A, et al. Survivin in esophageal cancer: an accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer. 2006;119:1717–22.PubMedCrossRef

20.

Wang Y, Zhu H, Quan L, et al. Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther. 2005;4:974–8.PubMedCrossRef

21.

Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23:527–37.PubMed

22.

Jang JS, Kim KM, Kang KH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2008;60:31–9.PubMedCrossRef

23.

Yang X, Xiong G, Chen X, et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135:1341–9.PubMedCrossRef

24.

Gazouli M, Tzanakis N, Rallis G, et al. Survivin −31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 2009;24:145–50.PubMedCrossRef

25.

Han CH, Wei Q, Lu KK, Liu Z, Mills GB, Wang LE. Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med. 2009;2:289–99.PubMed

26.

Wang YH, Chiou HY, Lin CT, Hsieh HY, Wu CC, Hsu CD, et al. Association between survivin gene promoter −31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology. 2009;73:670–4.PubMedCrossRef

27.

Cheng ZJ, Hu LH, Huang SJ. [Correlation of −31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma]. Ai Zheng. 2008;27:258–63.PubMed

28.

Yang L, Zhu H, Zhou B, et al. The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci. 2009;54:1021–8.PubMedCrossRef

29.

Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B. Potential influence of interleukin-1 haplotype IL-1 beta-511*T-IL-1RN*1 in conferring low risk to middle third location of esophageal cancer: a case–control study. Hum Immunol. 2008;69:179–86.PubMedCrossRef

30.

Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B. Association of interleukin-6 (-174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin Immunol. 2008;128:199–204.PubMedCrossRef

31.

Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Association of genetic polymorphisms of N-acetyltransferase 2 and susceptibility to esophageal cancer in north Indian population. Cancer Invest. 2007;25:340–6.PubMedCrossRef

32.

Jain M, Kumar S, Upadhyay R, Lal P, Tiwari A, Ghoshal UC, et al. Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. Cancer Biol Ther. 2007;6:1553–8.PubMedCrossRef

33.

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedCrossRef

34.

Borbely AA, Murvai M, Szarka K, Konya J, Gergely L, Hernadi Z, et al. Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol. 2007;60:303–6.PubMedCrossRef

35.

Gauderman WJ aMJ. QUANTO 1.1. A computer program for power and sample size calculations for genetic-epidemiology studies. http://hydrauscedu/gxe (2006).

36.

Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–42.PubMedCrossRef

37.

Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Role of GSTM3 polymorphism in the risk of developing esophageal cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:178–81.PubMedCrossRef

38.

Altieri DC, Marchisio PC. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 1999;79:1327–33.PubMed

39.

Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61–70.PubMedCrossRef

40.

Yang X, Xiong G, Chen X, et al. Survivin expression in esophageal cancer: correlation with p53 mutations and promoter polymorphism. Dis Esophagus. 2009;22:223–30.PubMedCrossRef

41.

Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer. 2002;87:883–7.PubMedCrossRef

42.

Konturek PC, Kania J, Kukharsky V, Ocker S, Hahn EG, Konturek SJ. Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. J Physiol Pharmacol. 2003;54:17–32.PubMed

43.

Wagner M, Schmelz K, Dorken B, Tamm I. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res. 2008;32:1054–60.PubMedCrossRef

Title: Role of Survivin Gene Promoter Polymorphism (−31G>C) in Susceptibility and Survival of Esophageal Cancer in Northern India
Authors: Rohit Upadhyay, MSc
Rohini Khurana, MD
Shaleen Kumar, MD
Uday Chand Ghoshal, DM
Balraj Mittal, PhD
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 3/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-010-1371-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of Survivin Gene Promoter Polymorphism (−31G>C) in Susceptibility and Survival of Esophageal Cancer in Northern India

Abstract

Background and Aim

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and Aim

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2011

Sentinel Node Biopsy by Indocyanine Green Retention Fluorescence Detection for Inguinal Lymph Node Staging of Anal Cancer: Preliminary Experience

Loss of E-cadherin and MUC2 Expressions Correlated with Poor Survival in Patients with Stages II and III Colorectal Carcinoma

Impact of Preoperative Ultrasonography and Fine-Needle Aspiration of Axillary Lymph Nodes on Surgical Management of Primary Breast Cancer

Preoperative Chemotherapy with Cisplatin and Docetaxel Followed by Surgery and Clip-Oriented Postoperative Chemoradiation in Patients with Localized Gastric or Gastroesophageal Junction Adenocarcinoma: Results from a Phase II Feasibility Study

Robotic Left Pancreatectomy for Pancreatic Solid Pseudopapillary Tumor

Correlation Between gp96 Expression and the Surgical Outcome in Patients With Esophageal Squamous Cell Carcinoma